NCT04186650View on ClinicalTrials.gov

Ex Vivo Gene Therapy Clinical Trial for RDEB Using Genetically Corrected Autologous Skin Equivalent Grafts

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

January 10, 2020

Primary Completion Date

June 9, 2027

Study Completion Date

June 9, 2027

Conditions
Epidermolysis Bullosa Dystrophica, Recessive
Interventions
BIOLOGICAL

COL7A1-SIN retroviral vector engineered autologous tissue-engineered skin

Graft of SIN RV-mediated COL7A1 gene-modified autologous skin equivalent

Trial Locations (1)

75743

Institut Imagine Necker Hospital, Paris

All Listed Sponsors
lead

Institut National de la Santé Et de la Recherche Médicale, France

OTHER_GOV